Thallion Completes Patient Enrollment of Phase II SHIGATEC Trial

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection. Dr. Allan Mandelzys, Thallion’s CEO, said in a statement, “The timely completion of patient recruitment and the two month patient follow [...]

Nature Medicine highlights Thallion’s E. coli treatment

In the wake of the deadly German outbreak of Escherichia coli, the July issue of prestigious Nature Medicine contains an article about research and treatments in development that highlights Thallion Pharmaceuticals (TSX:TLN) and its dual antibody Shigamabs. Shigamabs is designed to specifically neutralize the two types of shiga toxin secreted by pathogenic E. coli well before [...]

E. coli outbreak gives Thallion boost in visibility

The deadliest outbreak ever of E. coli, which has sickened more than 3,255 people in Europe to date, led to acute kidney failure in over 800 and killed 35, has raised the profile of Thallion Pharmaceuticals (TSX:TLN) and its product development candidate Shigamabs, an anti-toxin treatment for Shiga toxin-producing E. coli (STEC) infections. “Regardless of [...]

Thallion enrols first patient in high-dose Shigatec trial

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies have enrolled the first of an expected 21 patients in the high-dose cohort of their Phase 2 Shigatec trial to evaluate Shigamabs as a treatment for Shiga toxin-producing E. coli (STEC) infection. The company anticipates top line results to be available prior to the end of the year. “Following [...]

Thallion – LFB start Phase 2 Shigamabs trial

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies have initiated a Phase 2 trial, evaluating Thallion’s Shigamabs as a treatment for Shigatoxin-producing E. coli (STEC) infections, at 18 clinical sites in Argentina, Chile and Peru. STEC infection is an unmet medical need that affects more than 300,000 people in the industrialized world annually. No approved therapies exist, [...]

Thallion in $150-million pact to develop Shigamabs

Thallion Pharmaceuticals (TSX:TLN) is teaming up with LFB Biotechnologies of France to develop Shigamabs, Thallion’s product candidate for the treatment of Shigatoxin-producing bacterial, or STEC, infection. The accord, which is expected to close in the first quarter, provides for immediate funding by LFB of costs associated with re-initiating the Shigamabs program. In a statement, Thallion [...]